Executive
Page 1
Executive
Summary
There has been substantial progress in oncology over the last few years . Advances in therapeutics , particularly in immunotherapy , as well as diagnostic technologies has seen remarkable improvement in cancer survival rates over a range of major cancers . Despite these advances and with an ageing population , cancer remains a major economic and human burden . This COMPASS Research Report discusses how , in our view , developments in precision medicine in early diagnosis , surgery , radiotherapy and later stage therapies are driving progress in cancer care . We highlight the technologies and companies that are at the forefront of cancer care and creating the most attractive opportunities for investors .
Figure 1 : Cancer treatment modalities
Source : goetzpartners Research
RadioPh = Radiopharmaceuticals
Figure 1 illustrates our view of how the development of precision medicine will alter cancer treatment modalities providing a much more personalised and effective diagnostic treatment regimen . In principle , early diagnosis should lead to better outcomes . Current early screening technologies often fail to discriminate between aggressive and non-life-threatening indolent cancers . Advances in precision medicine particularly minimally invasive liquid diagnostics combined with an increasing use of multimodal regimens promise diagnosis that not only identifies the most aggressive forms of cancer , but also guides and monitors optimum therapy through companion and complementary diagnostics . High risk and development costs are a challenge for smaller new entrants . Tumour removal through surgery or radiotherapeutic ablation will remain the primary choice with earlier stage cancers . Adoption of robotic surgical technology should facilitate more targeted minimally invasive cancer surgery . Although increasingly widespread , opportunities for robotic new entrants may be limited by the large and growing international installed base of the long-established incumbent . Precision targeted radiotherapy (“ RT ”) already exists in proton and other particle beam technology . With progress slow , there is still an unmet opportunity for the development of well-engineered smaller footprint solutions that can be more rapidly and widely installed into healthcare facilities . With potential synergy with immunotherapy ,
Please see analyst certifications , important disclosure information , and information regarding the status of analysts on pages 91-94 of this research report .